BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Trevena Inc.

Headquarters: Chesterbrook, PA, United States
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Carrie L. Bourdow, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -0.03
Exchange/Ticker 1: Pink:TRVN
Exchange/Ticker 2: N/A
Latest Market Cap: $1,019,300

BioCentury | May 1, 2025
Management Tracks

Augustine follows up venture round with pair of C-suite hires

Plus: Management changes at Cidara, Fujifilm Cellular Dynamics and Transneural
BioCentury | Jul 2, 2024
Management Tracks

Patricia Drake to lead commercial at Innoviva’s specialty unit

Plus: Thomas Mehrling name CEO of Swiss biotech Release, and Tenaya CSO Hoey stepping down
BioCentury | Jan 7, 2022
Product Development

ACTIV PPP to deliver more COVID therapy data in 2022

The ACTIV adaptive master protocols are testing a range of COVID-19 therapeutic candidates
BioCentury | Sep 11, 2021
Management Tracks

New CEO for Eden following conviction of JHL execs

Plus: Mavilio, Loggia join Orchard and updates from PMV, Verseau, Apexigen, VectivBio, Protagonist and more
BioCentury | Sep 8, 2021
Management Tracks

Exelixis executives Schwab, Berndt pass away 

Plus: bluebird, ADC, Passage Bio and Insilico
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more  

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53
Items per page:
1 - 10 of 107